News and Announcements
Altech Chemicals Completes $2M Share Placement
- Published May 31, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Altech Chemicals Limited (ASX: ATC) is pleased to announce that following the unanimous approval of shareholders in a General Meeting held on 29 May 2017, the Company has now completed the $2 million placement of shares at $0.14 per share, to existing Malaysian cornerstone investor MAA Group Berhad.
KEY TAKEAWAYS:
- A$2 million received from share placement to existing cornerstone investor
- Shares issued at $0.14 per share
- Existing Malaysian shareholder MAA Group Berhad
- The Company has issued 14,285,714 shares to MAAG for this placement, taking the total shareholding of MAAG in the Company to 25,913,621 shares or 9.23% of total issued shares.
Funds raised from the share placement will be applied to the completion of detailed design and engineering of the Company’s proposed Malaysian high purity alumina (HPA) plant.
MAA Group Berhad (MAAG) is a Malaysian publicly listed insurance, investment, credit and finance group and an existing shareholder of Altech. Altech non-executive director, Tunku Yaacob Khrya is the executive chairman and majority shareholder of MAAG, consequently the placement of shares to MAAG was subject to the prior approval of Altech shareholders.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
